Fluticasone Furoate, Umeclidinium and Vilanterol

Bronchodilator & Anti-asthma Preps: Inhalants · Antimuscarinic/Beta-2 agonist/Corticosteroid

Indications

Maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Maintenance treatment of asthma.

Dosage

Inhaler: COPD: Adults: 1 actuation of 100/62.5/25 mcg once daily. Asthma: Adults: 1 actuation of 100/62.5/25 mcg or 200/62.5/25 mcg once daily as needed. Children: Not recommended.

Adverse Effects

COPD: Upper respiratory tract infection, pneumonia, bronchitis, oral candidiasis, headache, back pain, arthralgia, influenza, sinusitis, pharyngitis, rhinitis, dysgeusia, constipation, UTI, diarrhoea, gastroenteritis, oropharyngeal pain, cough, and dysphonia. Asthma: Pharyngitis/nasopharyngitis, upper RTI/viral upper RTI, bronchitis, RTI/viral RTI, sinusitis/acute sinusitis, UTI, rhinitis, influenza, headache and back pain.

Risk Factor (Pregnancy/Lactation)

Contraindications: Primary treatment of status asthmaticus or acute episodes of COPD or asthma requiring intensive measures. Relief of acute bronchospasm. Precautions: Monitor patients periodically for Candida albicans infection of the mouth and pharynx. Monitor patients for signs and symptoms of Pneumonia. Use with caution in patients with exisiting tuberculosis, fungal, bacterial, viral or parasitic infections, ocular herpes simplex. Taper patients slowly from systemic corticosteroids if transferring to Tresorol. Cardiovascular disorders. Discontinue if paradoxical bronchospasm occurs. Assess for decrease in bone mineral density initially and periodically thereafter. Pre-existing narrow-angle glaucoma. Pre-existing prostatic hyperplasia or bladder-neck obstruction. Convulsive disorders, thyrotoxicosis, diabetes mellitus and ketoacidosis. Hypokalemia. Hyperglycemia. Moderate or severe…

Interactions

Strong CYP450 3A4 inhibitors (e.g. ketoconazole). MAOIs and TCAs. Beta-blockers. Non-Potassium-Sparing Diuretics (loop or thiazide diuretics). Anticholinergics.

Advice to Patient

Rinse your mouth with water without swallowing following administration of Tresorol to help reduce the risk of oropharyngeal candidiasis. If it develops, treat it with appropriate local or systemic (i.e. oral) antifungal therapy. Be alert for signs and symptoms of acute narrow-angle glaucoma (e.g. eye pain or discomfort, blurred vision, visual halos or coloured images in association with red eyes from conjunctival congestion and corneal oedema). Report these symptoms immediate Report symptoms of urinary tract infection (e.g. difficulty passing urine, painful urination). Report if you experience: Palpitations, chest pain, rapid heart rate, tremor or nervousness.

Pharmacokinetics

FLUTICASONE FUROATE: Bioavailability: Absolute: 15.2%. Metabolism: Hepatic. Half-life elimination: 24 hrs. Time to peak: Within 0.5-1 hr. Excretion: Faeces (majorly). Urine (negligible). UMECLIDINIUM: Metabolism: Hepatic. Half-life elimination: 11 hrs. Time to peak: 5-15 mins. Excretion: Faeces (majorly). Urine (negligible). VILANTEROL: Metabolism: Hepatic. Half-life elimination: 11 hrs. Time to peak: 5-15 mins. Excretion: Urine (70%). Faeces (30%).

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.